Study Finds Delayed Menopause in Women with Polycystic Ovary Syndrome
A Finnish study of women born in 1966 found that only 3 percent of those with polycystic ovary syndrome reached late perimenopause or menopause by age 46. The condition appears to preserve a larger egg reserve that can improve fertility in the 40s.
foxnews.comWomen with polycystic ovary syndrome reach menopause later than women without the condition, according to a study published in Acta Obstetricia et Gynecologica Scandinavica. Researchers followed 1,849 women born in Finland in 1966 who received regular health examinations.
At age 31, 380 of the women met the diagnostic criteria for polycystic ovary syndrome. By age 46, only 3 percent of the women with the condition had entered late perimenopause or menopause. In comparison, 18 percent of women without the condition had reached that stage.
University Hospital said women with the condition are born with a larger reserve of eggs. This reserve keeps the ovaries crowded in younger years, which disrupts regular ovulation. As egg numbers decline naturally with age, the ovaries become less crowded.
Eggs can then mature and be released more easily, leading to more regular menstrual cycles. Piltonen noted that some women who had difficulty conceiving earlier reported pregnancies in their 40s. " The study also referenced a smaller Swedish study that found women with polycystic ovary syndrome reached menopause four years later on average.
Piltonen said the later drop in estrogen levels may reduce risks associated with menopause, including weaker bones and higher rates of heart disease. One cited study found women who reached menopause after age 55 lived two years longer on average than those who reached it before age 40.
The researchers suggested the condition may have offered reproductive advantages in earlier human populations when resources were limited.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
New ScientistPhase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic Cancer
A 500-person study found the once-daily pill halted or reversed tumor progression in nearly one-third of patients versus 10 percent on chemotherapy. Median survival rose from less than seven months to roughly 13 months.
Wildfire Insured Losses Hit $54 Billion in 2025, Highest on Record
A new analysis published Sunday found that insured losses from wildfires worldwide hit at least $54 billion in 2025, the highest level on record. The Los Angeles fires and blazes in South Korea and Spain drove the total.
nypost.comBundibugyo Ebola Strain Shows High Survival Rate in DRC; Suspected Cases Reported in Brazil and Italy
Four nurses and one laboratory worker have recovered from Ebola caused by the Bundibugyo strain in the Democratic Republic of Congo. Suspected cases linked to travel from affected countries are under investigation in Brazil and Italy.